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Graft vasculopathy is an accelerated form of coronary artery disease that occurs in transplanted hearts. Despite major
advances in immunosuppression, the prevalence of the disease has remained substantially unchanged during the last
two decades. According to the ‘response to injury’ paradigm, graft vasculopathy is the result of a continuous
inflammatory response to tissue injury initiated by both alloantigen-dependent and independent stress responses.
Experimental evidence suggests that these responses may become self-sustaining, as allograft re-transplantation
into the donor strain at a later stage fails to prevent disease progression. Histological evidence of endothelitis and
arteritis, in association with intima fibrosis and atherosclerosis, reflects the central role of alloimmunity and
inflammation in the development of arterial lesions. Experimental results in gene-targeted mouse models indicate that
cellular and humoral immune responses are both involved in the pathogenesis of graft vasculopathy. Circulating
antibodies against donor endothelium are found in a significant number of patients, but their pathogenic role is
still controversial. Alloantigen-independent factors include donor-transmitted coronary artery disease, surgical
trauma, ischaemia-reperfusion injury, viral infections, hyperlipidaemia, hypertension, and glucose intolerance. Recent
therapeutic advances include the use of novel immunosuppressive agents such as sirolimus (rapamycin), HMG-CoA
reductase inhibitors, calcium channel blockers, and angiotensin converting enzyme inhibitors. Optimal treatment of
cardiovascular risk factors remains of paramount importance.
© 2003 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.
Introduction
Accelerated vascular disease is a characteristic
feature of chronic graft dysfunction in organ trans-
plantation. As such, accelerated coronary artery
disease is one of the most discouraging aspects in
heart transplantation.1,2 The disease is the third
leading cause of death, after infection and rejec-
tion, in the first year after heart transplantation,
and the first leading cause of death in subsequent
years. In a multi-institutional study, 42% of heart
transplanted patients had abnormal coronary angio-
grams, and 7% of patients had severe coronary
artery disease by 5 years post-transplant.3 Disease-
related events including death and re-
transplantation had an actuarial incidence of 7% at
5 years, and occurred in two of three patients with
angiographically severe coronary artery disease. It
should be noted that coronary angiography, which
has been the main modality of invasive assessment
of graft vasculopathy, is insensitive. Intravascular
ultrasound (IVUS), which can detect early intimal
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thickening, has revealed a much higher incidence
of the disease (up to 75% at 1 year after trans-
plantation).4,5 Virtually all 5-year survivors have
histological evidence of graft vasculopathy.6
The first section of the present review briefly
discusses the clinical aspects of cardiac allograft
vasculopathy, with particular emphasis on endo-
thelial dysfunction as an early manifestation of the
disease. The main focus of the review is the patho-
genesis of graft coronary vasculopathy, which
involves both immunologic and nonimmunologic
risk factors. Therapeutic approaches are briefly
discussed in the final section.
Clinical aspects of graft vasculopathy
Classic angina as a symptom of graft coronary
vasculopathy is rarely perceived because the trans-
planted heart is denervated. Consequently, the
disease may be manifested by shortness of breath,
decreased exercise capacity, syncope, arrhyth-
mias, or heart failure. Unfortunately, the first
manifestation may be acute myocardial infarction
or sudden death. Therefore, patients should be
evaluated on an annual basis for the presence of
coronary artery disease. IVUS is more sensitive than
coronary angiography with respect to early arterial
lesions. Serial echocardiography is useful to
detect progressive deterioration of left ventricular
function as a result of myocardial ischaemia.
Dobutamine stress echocardiography early after
transplantation has been shown to predict develop-
ment of graft vasculopathy and clinical events.7
Angiographic and histological findings
Angiographic features in patients with graft cor-
onary vasculopathy are variable. Arterial lesions
are typically concentric and involve the entire cor-
onary tree, including the small intramyocardial
branches. However, isolated lesions closely resem-
bling atherosclerotic lesions in native vessels also
occur. A classification system for luminal narrowing
based on angiography was proposed by Gao and co-
workers.8 Category A referred to discrete, tubular
lesions. Histological analysis showed that nearly
half of type A lesions consisted of atheroma.9 Cat-
egory B denoted distal lesions that are usually
characterized by fibrous intimal thickening, while
category C referred to diffusely irregular patterns
of narrowing. Fibrous intimal hyperplasia can be
associated with arteritis with mononuclear cell in-
filtrates and obliterating endothelitis, eventually
leading to destruction of elastic fibres and thinning
of the muscular media.
The basic determinants of coronary narrowing
are intimal thickening and vascular remodelling.
Serial IVUS has shown that remodelling of the
arterial wall can compensate for moderate intimal
thickening.10,11 Compensatory remodelling is
greater in excentric than concentric lesions, poss-
ibly due to greater compliance of the normal portion
of the vessel wall.11 Besides compensatory enlarge-
ment, constrictive changes (negative remodelling)
has also been identified and shown to be the
most important predictor of the severity of focal
stenoses.10 Constrictive remodelling with a de-
crease in total vessel volume predominates in the
first year after transplantation, whereas a slight
compensatory enlargement can be observed at
later time points. Recent data in a mouse model
show that matrix metalloproteinases (MMPs)
involved in the degradation and remodelling of
extracellular matrix play an important role in
constrictive vascular remodelling.12
Endothelial dysfunction as an early stage of
graft vasculopathy
Endothelial dysfunction can be clinically detected
as abnormal vasomotion in response to endo-
thelium-dependent stimuli such as acetylcholine,
substance P, the cold-pressure test, and dynamic
exercise.13–15 Reduced vasodilation, or paradoxical
vasoconstriction, in response to acetylcholine
occurs even in the absence of angiographic abnor-
malities.16 Its predictive value is controversial. One
study showed that acetylcholine-induced vaso-
constriction early after transplantation may resolve
over the following months, suggesting that it re-
flects a reversible insult to the endothelium around
the time of transplantation.17 This early insult
involves ischaemia-induced release of cytokines
such as interleukin (IL)-2 and IL-6, and the potent
vasoconstrictor endothelin-1.18–20 In another study,
however, early vasomotor abnormalities predicted
the development of graft vasculopathy at 1 year
post-transplant.21 Moreover, in a recent study
using serial IVUS and Doppler flow-wire measure-
ments, annual decrements in coronary endothelial
function were associated with progressive intimal
thickening, while abnormal vasomotor response to
acetylcholine preceded the development of clinical
endpoints.22 Together, these observations suggest
that endothelial dysfunction may represent an
early and potentially reversible stage of graft
vasculopathy. However, sustained endothelial dys-
function may reflect permanent vascular injury,
with or without structural abnormalities.
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Vasodilation during dynamic exercise depends on
endothelial NO release. Both epicardial coronary
vasodilation and coronary flow reserve during exer-
cise were progressively impaired in cardiac trans-
plant recipients 2–3 years post-transplant.23 In
contrast, pharmacological flow reserve was main-
tained. These results suggested progressive graft
microvascular endothelial dysfunction in heart
transplanted patients. However, coronary blood
flow measurements by positron-emission tomogra-
phy showed that coronary blood flow at rest is
increased in transplanted patients and is respon-
sible, at least in part, for decreased coronary flow
reserve during exercise.24
Role of alloimmunity in the
pathogenesis of graft vasculopathy
The simple observation that while graft coronary
arteries develop vascular lesions, the host's native
arteries are spared suggests a crucial role for allo-
immunity in graft vasculopathy. This is consistent
with experimental evidence that hearts trans-
planted into a genetically different recipient are
affected, whereas those transplanted into a geneti-
cally identical recipient are spared. Furthermore,
protocols that induce donor-specific immune toler-
ance prevent graft vasculopathy in experimental
models.25
The number of HLA mismatches, as well as the
number of rejection episodes and their duration
have been identified as alloantigen-dependent risk
factors.26,27 However, differences in the long-term
outcome between patients who experienced an
acute rejection in the first year after heart trans-
plantation and those who did not are small.28 Thus,
the relationship between acute cellular rejection
and cardiac allograft vasculopathy remains
controversial.29–31
Role of the endothelium in alloimmunity
Endothelial cells of coronary arteries are the first
biological interface between the transplanted
donor heart and circulating immunocompetent
cells of the recipient. A variety of insults including
brain death,32 organ preservation and surgical
trauma,33 ischemia-reperfusion,34,35 alloimmune
responses to donor antigens,36 cytomegalovirus
infection,37 cyclosporine toxicity,38,39 hyperlipi-
daemia and glucose intolerance40 can ‘activate’
endothelial cells. The concept of ‘activated’ endo-
thelium is not precisely defined, but it includes
expression of major histocompatibility complex
(MHC) molecules and adhesion molecules (e.g.,
E-selectin), secretion of cytokines and chemokines,
and expression of molecules that provide costimu-
latory signals for T and B cell activation. In turn,
activated CD4+ T cells stimulate the expression of
human leukocyte antigens (HLA) class-II molecules
on endothelial cells, subsequent to HLA class-I
detection by CD8+ T cells. HLA and other donor
antigens expressed on graft endothelial cells can
elicit a sustained alloimmune reaction.41 Clinical
evidence suggests that HLA donor-recipient match-
ing is an independent predictor of survival in heart
transplantation.26 In the Collaborative Transplant
Study, cardiac transplant recipients receiving a
graft with no or only one HLA-A, B, or DR mismatch
(n=128 out of 8331; 1.5%) had a 83±4% 3-year graft
survival rate as compared to 76±2% for those with
two mismatches (n=439) and 71±1% for those with
three to six mismatches (n=7764).42 Although this
association was highly significant (P<0.001), the
impact on the clinical outcome was limited (6.6%
difference in 3-year graft survival rates between
two and three or more mismatches). In the clinical
setting, donor organ shortage and the need for
rapid transplantation in many patients with ter-
minal heart failure do not allow for allocation of
donor organs based on HLA matching. Nevertheless,
information about HLA matching may be of some
usefulness to guide early immunosuppression. Pro-
spective HLA matching should be considered for
retransplantation or in presensitized recipients.
Besides the well-established activation of the
direct pathway of allorecognition,43 endothelial
cells can activate T cells via the indirect pathway,
which involves processing and presentation of pep-
tides derived from allogeneic HLA molecules by
recipient antigen presenting cells (APCs) such as
dendritic cells.41 Importantly, dendritic cell inva-
sion has been shown to be increased on activated
endothelial cells and after blocking of the endo-
thelial nitric oxide synthase.44 Recently, it has been
shown that direct CD8+ T cell activation by endo-
thelial cells can trigger acute cardiac allograft
rejection.45
Cellular alloimmune responses
Experiments in rodent models of allograft vascu-
lopathy have shown that arterial lesions first de-
velop as endothelitis and subsequently progress to
smooth muscle cell-rich fibrosis.46 T cells (CD4+,
CD8+, NK cells), macrophages, and dendritic cells
have been evidenced in arterial lesions. These cells
secrete a myriad inflammatory mediators including
cell adhesion molecules, cytokines, chemokines,
growth factors and macrophage activators, as well
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as proteases that degrade extracellular matrix
proteins.
Depletion of CD4+, but not CD8+, T cells pre-
vented arterial lesion formation in an experimental
model.47 Functional CD4+ T cell responses have been
subdivided in Th1- and Th2-type responses. Their
respective roles were studied using mice deficient
in interferon- (IFN-) or Stat4 (which regulate
Th1-type responses) or in IL-10 (which mediates
Th2-type responses) as graft recipients. Cardiac al-
lografts placed in IFN- or Stat4-deficient recipients
had decreased graft vasculopathy, whereas those
placed in IL-10-deficient recipients had increased
vascular occlusion.48–50 Increased vascular lesions
were observed in recipient mice deficient in
inducible nitric oxide synthase (iNOS) or trans-
forming growth factor- (TGF-), suggesting an
immunomodulatory role for these molecules.51,52
Humoral alloimmune responses
Both experimental and clinical studies have re-
ported an association between antibody production
after heart transplantation and graft vasculopathy.
Heterotopic heart transplantation between mice
bearing MHC class-I alone, class-II alone or minor
mismatches, in combination with short immuno-
suppression, resulted in vascular lesions within 4–8
weeks.53 Transplantation of B10.A mouse hearts
into B10.BR recipients (MHC class-I mismatch only)
resulted in high-titer anti-donor antibody produc-
tion and severe graft vasculopathy.54 Conversely,
low-titer anti-donor antibodies and mild arterial
disease were observed in the reciprocal donor-
recipient strain combination. However, graft vas-
culopathy in this combination was induced by
treating recipients with an anti-donor antiserum
made in a separate strain. Furthermore, hearts
transplanted into B cell-deficient mice that are
incapable of producing immunoglobulins developed
only minor disease.55 Hearts transplanted into
immunodeficient SCID mice survived indefinitely
with no significant vasculopathy. However, vascu-
lar lesions rich in macrophages and NK cells
developed in SCID mice upon treatment with an
antiserum reactive with donor antigens. Together,
these findings demonstrate that humoral responses
play a key role in the pathogenesis of graft vascu-
lopathy, but cellular responses are also involved.
In clinical heart transplantation, circulating anti-
HLA antibodies have been associated with poor
survival.56,57 Anti-endothelial antibodies detected
at 1 and 2 years post-transplant were found in
patients who had developed graft vasculopathy at
this time.58 These antibodies were reactive with as
many as 40 peptides from endothelial cells.59 The
most abundant of these antibodies were reactive
with the intermediate filament vimentin and were
associated with graft vasculopathy. Antibodies
against endothelial cell surface molecules such as
MHC class-I and intercellular adhesion molecule
(ICAM)-1 were associated with endothelial acti-
vation and release of growth factors.60,61 Increasing
evidence indicates that a large number of potential
antigens are released from the allograft to be pro-
cessed and presented via the indirect pathway by
recipient APCs.62 Antibody responses against non-
HLA and minor antigens have been reported.58,59,63
Role of alloantigen-independent factors
in the pathogenesis of graft
vasculopathy
According to the ‘immunologic view’, centred on
the overwhelming importance of alloimmunity,
graft vasculopathy has long been referred to as
chronic rejection. However, this term is misleading
because it does not adequately take alloantigen-
independent factors into account. Alternatively,
the ‘response to injury’ concept, first formulated
as an explanation for naturally occurring athero-
sclerosis,64 may provide a theoretical framework
for understanding graft vasculopathy as well. This
concept dictates that vascular lesions are the result
of cumulative vessel injury induced both by allo-
immune responses and by nonspecific insults. Endo-
thelial injury triggers a cascade of ‘tissue repair’
mechanisms that involve vascular cell prolifer-
ation, fibrosis, and vascular remodelling. However,
exuberant ‘tissue repair’ leads to intimal thicken-
ing and luminal narrowing. At a later stage, non-
specific mechanisms may become self-sustaining
and promote arterial lesion progression even in an
immunologically friendly environment, as exper-
imental late allograft re-transplantation back into
the donor strain does not prevent progression of the
disease.65,66
Nonimmunologic risk factors
Studies evaluating the contribution of nonimmuno-
logic risk factors to graft vasculopathy have re-
ported variable results. A multi-institutional
coronary angiography study identified donor char-
acteristics such as older age, male gender and
hypertension, as well as recipient characteristics
such as older age and male gender as risk factors.3
Moreover, multicentre IVUS study identified older
donor age and recipient body mass index as risk
factors for coronary intimal thickening.67
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Input injury
‘Input injury’ designates the burden in the organ at
the time of transplantation. It includes both donor-
transmitted disease and graft injury as a result of
brain death, donor maintenance, organ removal
and preservation, and surgical trauma.33 Studies on
kidney transplantation have shown that organs
from live donors, even in an immunologic mis-
match setting, have a significant advantage over
cadaveric donors.32 Pre-existing coronary artery
lesions are not infrequent, even in young donors
(56% of donors aged 32±12 years, as assessed by
IVUS). However, donor-transmitted lesions do not
seem to enhance accelerated graft vasculopathy
after heart transplantation.68
Ischaemia-reperfusion injury
Interruption of blood supply during ischaemia leads
to anaerobic metabolism, depletion of adenosine-
triphosphate (ATP), dysfunction of membrane ionic
ATP-dependent pumps, entry of calcium and
sodium into the cell. Upon reperfusion, highly
reactive hydroxil radicals are generated, which
stimulate P-selectin expression on endothelial
cells. Activated endothelial cells also produce
platelet activating factor (PAF) that interacts with
the PAF receptor on neutrophils.34 Acting in con-
cert, PAF and P-selectin promote neutrophil acti-
vation and induce 2-integrin expression, resulting
in 2-integrin binding to ICAM, which mediates firm
attachment of neutrophils to endothelial cells. To-
gether, these observations suggest that ischaemia/
reperfusion injury plays a major role in graft
vasculopathy.
Cytokines and chemokines
Cytokines are secreted pro-inflammatory mol-
ecules that regulate leukocyte activation. The Th1
subset of CD4+ cells produces IFN-, IL-2, and TGF-
1, whereas the Th2 subset produces IL-4, IL-5,
IL-6, IL-9, IL-10, and IL-13. As mentioned, IFN-
seems to promote, whereas IL-10 protects against
graft vasculopathy.48,50 Chemokines (chemo-
attractant cytokines) regulate the recruitment of
leukocytes to the allograft.69 Expression of several
chemokines including monocyte chemoattractant
protein (MCP)-1, MCP-3, IL-8 and RANTES was dem-
onstrated in transplanted human hearts. RANTES
production promoted monocyte adhesion to acti-
vated endothelium and arterial lesion formation in
a graft vasculopathy model.70 Mice deficient in
the CC chemokine receptors (CCRs)-1 and 5 had
markedly attenuated cardiac allograft rejection in
the absence of immunosuppression.71 Short-term
treatment with low-dose cyclosporine, which failed
to prevent rejection in wildtype mice, induced
indefinite allograft acceptance with no significant
vasculopathy in CCR-1-deficient mice. Consist-
ently, administration of a CCR-1 antagonist delayed
heart transplant rejection in an experimental
model.72 These results suggest an important
role for chemokines in allograft rejection and
vasculopathy.
Cytomegalovirus (CMV) infection
CMV infection, the most frequent infectious
complication in transplanted patients, can cause
vascular inflammation (endothelitis and arteritis).
Both clinical and experimental evidence points
toward a role for CMV in the pathogenesis of graft
atherosclerosis.73–76 Prophylactic therapy with
ganciclovir has reduced the incidence of CMV dis-
ease, but not in the group at highest risk (i.e.,
seronegative recipients of grafts from seropositive
donors). In a post-hoc analysis, ganciclovir prophy-
laxis was associated with decreased intimal thick-
ening, reduced coronary artery disease and
improved survival.77 Moreover, CMV hyperimmune
globulin in combination with ganciclovir may be
more protective than ganciclovir alone.78 These
issues need to be further addressed in prospective,
randomized trials.
Metabolic factors
Last but not least, conventional vascular risk fac-
tors such as hyperlipidaemia, glucose intolerance
and hypertension, which are highly prevalent in
transplanted patients on current immunosuppres-
sive regimens, play contributory roles in graft
endothelial dysfunction and transplant vasculopa-
thy.79 Presence of multiple vascular risk factors
was associated with severe impairment of coronary
vasodilation during exercise in cardiac transplant
recipients.80 At necropsy, histological analysis of
transplanted hearts showed frequent atheromata
with diffuse intra- and extra-cellular lipid accumu-
lation in both intimal and medial walls.81 Mean
total cholesterol content in coronary arteries was
more than 10-fold higher than in comparable donor
age-matched native vessels. Extent of lipids in the
arterial walls was highly correlated with mean
cumulative cyclosporine and prednisone doses.81
Thus, the importance of metabolic factors in
the development of graft vasculopathy should
be emphasized, particularly because effective
treatments for these risk factors are available.
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Therapeutic approaches to graft
vasculopathy
The optimal treatment prophylaxis for graft vascu-
lopathy has not been established. Current treat-
ments are moderately effective in delaying the
development of arterial lesions, but they do not
completely prevent it. Experimental evidence that
improved immunosuppression can prevent graft
vasculopathy suggests that optimized immunosup-
pression is a primary goal in treatment prophylaxis
of the disease.25
Most current protocols are based on
cyclosporine-A or tacrolimus (FK506), calcineurin
inhibitors that block early T-cell activation, and on
the purine synthesis inhibitors azathioprine and
mycophenolate mofetil. In most centres, steroids
are weaned when endomyocardial biopsies show
low or negative rejection scores. Most cardiac
transplant recipients can be maintained on steroid-
free regimens, thus avoiding the detrimental
metabolic effects of these drugs.82 Low-dose
cyclosporine protocols have been evaluated in
an attempt to reduce endothelial toxicity; how-
ever cyclosporine dose reduction at 1 year post-
transplant was not associated with improved
coronary artery diameter at 2 and 3 year follow-
up.83 These negative results may be due to the late
onset of low-dose cyclosporine, as initial lesions
develop during the first year post-transplant. This is
consistent with another report showing that aug-
mented immunosuppression started in the first year
post-transplant is associated with arterial lesion
regression in 92% of patients, as compared to 40%
when started in the second year post-transplant.84
Daclizumab, a hybrid humanized interleukin-2
receptor antibody, has been effective in pre-
venting allograft rejection in clinical heart
transplantation.85 The immunosuppressive and
anti-proliferative drug sirolimus (rapamycin), an
inhibitor of interleukin-2-mediated signal transduc-
tion pathways, can be used as a rescue drug when
cyclosporine is contraindicated or ineffective.86
Sirolimus has been shown to reverse graft vascu-
lopathy in experimental studies and initial clinical
trials.87–89 Preliminary results of an ongoing multi-
centre trial suggest that sirolimus treatment is
associated with reduced coronary artery disease in
cardiac transplant recipients.89 If the beneficial
effects of sirolimus are confirmed by definitive
results, this drug may represent a major advance in
the prevention of graft vasculopathy.
Only a few small trials have compared different
immunosuppressive regimens for prevention of
graft vasculopathy. The combination of tacrolimus
and mycophenolate mofetil was superior to
tacrolimus and azathioprine, and comparable
to cyclosporine and azathioprine, with respect to
coronary vasomotor function early after transplan-
tation; however, this combination failed to reduce
coronary intimal thickening.90 Another study
showed no significant differences in vascular
occlusion between mycophenolate mofetil and
azathioprine immunosuppression.91 In a prospec-
tive IVUS trial, cyclosporine was slightly, although
not significantly, more effective than tacrolimus
in preventing graft vasculopathy in the first year
post-transplant.92
The calcium channel blocker diltiazem started
early after transplantation was associated with re-
duced coronary artery narrowing, reduced mor-
tality from graft arteriosclerosis, and reduced
overall mortality at 1 year post-transplant.93
Angiotensin-converting enzyme (ACE) inhibitors
may also be effective in delaying development of
graft vasculopathy.94
The only established clinical treatment is routine
therapy with 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) inhibitors (statins). Pravastatin im-
proved 1-year survival in a prospective study.95
Notably, protection was independent of changes in
lipid levels, probably reflecting immunomodulation
such as reduced natural killer cell cytotoxicity,95
decreased cytokine activity and/or improved cor-
onary endothelial function.96 Simvastatin reduced
graft coronary artery disease and overall mortality
after heart transplantation in a 4-year follow-up
trial.97
Once transplant vasculopathy is manifest, percu-
taneous transluminal coronary angioplasty (PTCA)
and coronary artery bypass grafting (CABG) offer
palliative options in cases characterized by a single
or a few focal lesions, as opposed to diffuse luminal
narrowing.98,99 Although restenosis was typically
more frequent in dilated graft versus native cor-
onary lesions, IVUS studies have identified exten-
sive early recoil as a major cause for restenosis in
cardiac transplant recipients.99 Consequently,
intravascular stent implantation recently resulted
in improved outcome in patients with focal cor-
onary obstruction. In a single centre experience,
treatment of 41 patients (75 lesions, 85 stents)
resulted in a success rate of 98% with a 6-month
restenosis rate of 14%.99 A similar restenosis rate
(18%) after stent implantation was reported by
another one-centre study, which favourably com-
pared to a 60% restenosis rate with PTCA in
the absence of stenting.100 Although only limited
experience is available regarding the surgical
approach with CABG, this should be considered in
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selected patients with focal coronary lesions not
suitable for PTCA.
In summary, both alloantigen-dependent and in-
dependent factors are involved in the development
of cardiac allograft arteriopathy. Treatment
prophylaxis with HMG-CoA reductase inhibitors
and, possibly, calcium channel blockers and ACE
inhibitors may delay arterial occlusion. Preliminary
clinical results using sirolimus are very encourag-
ing,89 and long-term results of an ongoing multi-
centre trial with this drug are eagerly awaited.
Novel immunomodulating approaches (e.g., T-cell
costimulatory blockade with CTLA4-Ig or CD40-Ig)
have shown promising effects in experimental
models. Optimized treatment of non-immunologic
cardiovascular risk factors remains of paramount
importance.
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